Insights
Insights From Our Experts
Articles
Winners Circle Podcast: How EVERSANA Built an 80/20 AI Model That Works
In a Winners Podcast episode, Faruk Capan, Chief Innovation Officer at EVERSANA, discusses how AI can transform pharmaceutical marketing — without compromising compliance. Pharmaceutical marketing operates under constraints most industries never face. Every claim must be compliant,…
Medical Affairs Under Pressure: A Modern Operating Model for the Next Era
Posted by
Samie Ahmed, PharmD, MS , Michael DeLuca, PharmD, MBA, MSRA , Mary Mehrabian, PharmD, BCGP, BCMAS on April 29, 20264/29/26
Medical Affairs is facing sustained structural and operational complexity. As its strategic role expands across the product lifecycle, Medical Affairs is expected to deliver launch excellence, shape evidence strategy, generate actionable insights, and demonstrate measurable organizational…
The Future of Pharmaceutical Deployment
The ground is shifting beneath the feet of the pharmaceutical industry. The long-standing formula for commercial success used to include building massive, dedicated sales forces. Now, it has become a liability in an era of patent cliffs, cost…
You Can Build AI In House.
But Should You?
AI is no longer an experiment in pharma. It is an executive mandate tied to growth, efficiency and competitive advantage. Most large pharmaceutical organizations have already committed to investing. The harder question is how to translate…
The Strategic Advantage: Why a Vendor-Neutral Approach is Key to PV Success
When implementing a new pharmacovigilance system, the greatest threat isn’t a technical glitch, but the inherent bias that comes with a vendor-led solution. This subtle conflict of interest often results in a system designed for the vendor’s benefit,…
From Experimentation to Ownership: Why the Future Belongs to Companies That Own AI
At Google Cloud Next, EVERSANA’s Chief Innovation Officer, Faruk Capan, joined leaders from Salesforce and Palo Alto Networks for a discussion centered on a challenge many organizations are facing right now: moving from experimenting with AI to operating with it at scale. What became…
A New Standard for Copay Excellence: How Pharma Can Rethink Affordability
As out‑of‑pocket costs rise and insurance designs grow more complex, traditional copay models are being pushed to their limits. High‑deductible plans, accumulator and maximizer programs, and growing payer and PBM variability are fundamentally reshaping how manufacturer affordability programs operate. In a…
Beyond the Pilot: Scaling the Steep Climb of AI in Drug Safety
Artificial Intelligence in pharmacovigilance often feels like a distant summit for emerging biopharma companies. Many successfully launch a pilot program only to face the harsh operational reality of scaling: crippling capital investment, a scarcity of specialized…
Build the Launch, Then Cut the Deal: A Smarter Playbook for Emerging Biotech Value
Posted by
Farah Toublan, Ph.D. , Xavier Aparicio , Mike DeLaroche , Maneesh Gupta , Faruk Abdullah on April 13, 20264/13/26
For emerging and late-stage biotechs, out-licensing is often viewed as the safer path. Data from our five-year analysis of real-world licensing deal outcomes tells a different story. In this paper, EVERSANA experts break down two critical decisions: Out-license vs. launch independently? If the former, at which stage will out-licensing maximize transactional value? Our experts dive into the key launch…
Stay Ahead of Change with NAVLIN Daily’s Global Policy Watch
Pharmaceutical pricing policy has become increasingly global over the past few years, with changes happening at breakneck pace. The rise of Most-Favored Nation (MFN) in 2025 rapidly accelerated this trend, making it more essential than ever…